Yao Z, Auchampach J A, Pieper G M, Gross G J
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee 53226.
Cardiovasc Res. 1993 May;27(5):832-8. doi: 10.1093/cvr/27.5.832.
The major objective of the present study was to determine the effects of a new endotoxin analogue, monophosphoryl lipid A (MLA), on myocardial infarct size in dogs. A second aim was to determine if potential cardioprotective effects of MLA might be mediated via an enhancement of antioxidant defence mechanisms.
Barbiturate anaesthetised dogs were subjected to 60 min left circumflex coronary artery occlusion followed by 5 h reperfusion. Either of two different doses of MLA (30 and 100 micrograms.kg-1) or an equivalent volume of vehicle were given intravenously 24 h prior to the infarct experiments. Transmural myocardial blood flow was measured at 30 min of occlusion by the radioactive microsphere technique and infarct size was determined at the end of 5 h of reperfusion by triphenyltetrazolium staining. Tissue catalase and myeloperoxidase activities were measured at 5 h of reperfusion as indices of antioxidant activity and neutrophil infiltration, respectively.
There were no significant differences between groups in systemic haemodynamic variables, myocardial oxygen demand, ischaemic bed size, or coronary and collateral blood flow to the ischaemic region. However, administration of MLA produced a marked dose dependent reduction in myocardial infarct size: 19.8(SEM 3.7)% and 14.1(2.5)%, respectively, v 32.7(2.9)% in the vehicle control group, p < 0.05. Pretreatment with either 30 or 100 micrograms.kg-1 of MLA resulted in small increases in tissue catalase activity in the non-ischaemic region of the heart: 0.169(0.033) and 0.197(0.013) K.g-1, respectively, v 0.136(0.013) K.g-1 tissue in the control; however, the increases were not statistically significant by ANOVA. Myeloperoxidase activity in the border zone immediately adjacent to the infarct was markedly decreased in both MLA treated groups: MLA 30 micrograms.kg-1, 2.69(0.82); MLA 100 micrograms.kg-1, 2.49(0.47), v control group, 5.81(1.20) units.g-1 tissue; p < 0.05.
These data are the first to show a marked cardioprotective effect of a lipid A derivative of endotoxin in an in vivo model of myocardial infarction. Although the mechanism responsible for the reduction in infarct size by MLA is unknown, a reduction in neutrophil migration at the site of ongoing tissue injury, the border zone, may be partially responsible.
本研究的主要目的是确定一种新型内毒素类似物单磷酰脂质A(MLA)对犬心肌梗死面积的影响。第二个目的是确定MLA潜在的心脏保护作用是否可能通过增强抗氧化防御机制介导。
用巴比妥类药物麻醉犬,使其左回旋支冠状动脉闭塞60分钟,然后再灌注5小时。在梗死实验前24小时,静脉注射两种不同剂量的MLA(30和100微克·千克-1)或等量的赋形剂。在闭塞30分钟时,通过放射性微球技术测量透壁心肌血流量,并在再灌注5小时结束时,通过三苯基四氮唑染色确定梗死面积。分别在再灌注5小时时测量组织过氧化氢酶和髓过氧化物酶活性,作为抗氧化活性和中性粒细胞浸润的指标。
各组在全身血流动力学变量、心肌需氧量、缺血床大小或缺血区域的冠状动脉和侧支血流量方面无显著差异。然而,给予MLA可使心肌梗死面积显著剂量依赖性降低:分别为19.8(标准误3.7)%和14.1(2.5)%,而赋形剂对照组为32.7(2.9)%,p<0.05。用30或100微克·千克-1的MLA预处理可使心脏非缺血区域的组织过氧化氢酶活性略有增加:分别为0.169(0.033)和0.197(0.013)千单位·克-1,而对照组为0.136(0.013)千单位·克-1组织;然而,经方差分析,这些增加无统计学意义。在两个MLA治疗组中,紧邻梗死灶的边缘区髓过氧化物酶活性均显著降低:MLA 30微克·千克-1组为2.69(0.82);MLA 100微克·千克-1组为2.49(0.47),而对照组为5.81(1.20)单位·克-1组织;p<0.05。
这些数据首次表明内毒素的脂质A衍生物在心肌梗死的体内模型中具有显著的心脏保护作用。虽然MLA降低梗死面积的机制尚不清楚,但中性粒细胞在持续组织损伤部位即边缘区的迁移减少可能部分起了作用。